Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
722 results about "Schizophrenia disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors
The present invention relates to novel compounds, in particular novel thieno-pyridine and thieno-pyrimidine derivatives according to Formula (I), wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
Owner:ORTHO MCNEIL JANSSEN PHARMA
Phospholipase c beta1 (plcbeta1) knockout mice as a model system for testing schizophrenia drugs
The present invention relates to a method for screening therapeutic drugs of schizophrenia using an animal model of the disease. More specifically, this invention relates to a screening method based on the phospholipase C β1 (PLCβ1) knockout mouse as an animal model of schizophrenia with all the major symptoms of the human disease. This knockout mouse exhibits symptoms similar to human schizophrenia such as locomotor hyperactivity, impaired prepulse inhibition of the startle response, lack of barbering and nesting behaviors, socially subordinate status, impaired learning, and lack of type II theta rhythm which has been implicated in working memory. Thus, the knockout mouse of the present invention can be useful as an animal for screening therapeutic drugs against schizophrenia.
Owner:KOREA INST OF SCI & TECH
Inhibitors of glutaminyl cyclase
The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
Owner:VIVORYON THERAPEUTICS NV
Identification of ligands by selective amplification of cells transfected with receptors
InactiveUS20050244862A1Increase ratingsReduced responseCompound screeningApoptosis detectionConstitutively activeSerotonin 2A Receptors
The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor / ligand interactions. The present invention also relates to a method of identifying compounds which act as inverse agonists of the 5-HT2A receptor, the method comprising contacting a constitutively active 5-HT2A receptor with at least one test compound and determining any decrease in the amount of basal activity of the receptor so as to identify a test compound which is an inverse agonist of the 5-HT2A receptor. Such inverse agonists may be used in the treatment of schizophrenia and related psychoses.
Owner:ACADIA PHARMA INC
Substituted amides
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Amide compound
The present invention aims to provide a prophylactic or therapeutic agent for schizophrenia and the like, containing the compound of the present invention having a GPR52 agonist activity. A compound represented by the following formula (I) or a salt thereof:wherein,A is —CONH or the like,B is a hydrogen atom or a substituent,ring Cy1 is a benzene ring or the like,X1, X2 and X3 are each independently —CH═ or —N═ or the like,ring Cy2 is a carbon ring or the like,Z is a carbon atom or a nitrogen atom,L is a bond or the like,n is 1 or 2,Rb is a hydrogen atom or a substituent, andring Cy3 is a benzene ring or the like.
Owner:TAKEDA PHARMACEUTICALS CO LTD
Dihydrobenzofuran derivatives and uses thereof
InactiveUS20060241176A1Increase in body weightUseful in treatmentBiocideNervous disorderFuranCentral nervous system
Compounds of formula I are described herein which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. or pharmaceutically acceptable salts thereof, wherein each of R1, R2, R3, R4, Rx, Ry, and n are as defined herein. Such compounds, and compositions thereof, are useful for treating a variety of central nervous system disorders such as schizophrenia.
Owner:WYETH
Exo-R-mecamylamine formulation and use in treatment
InactiveUS20020016370A1Convenient treatmentImprove Medication AdherenceBiocideUrea derivatives preparationStimulantS syndrome
A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
Owner:UNIV OF SOUTH FLORIDA
3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
Owner:ADDEX PHARM SA
Composition and Method for Treatment of Depression and Psychosis in Humans
ActiveUS20140018348A1Eliminate side effectsReduce side effectsBiocideNervous disorderPsychosisAntagonist
Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and / or antidepressant medications and also containing an NMPAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and / or antipsychotic effective amounts.
Owner:GLYTECH
Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
The present invention relates to methods for treating or controlling schizophrenia in a mammal using compounds having the Formula (I), wherein M1 and M2 are defined in the application.
Owner:ORTHO MCNEIL JANSSEN PHARMA
Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
ActiveUS8598155B2Ease of preparation and detectabilityGood metabolic stabilityBiocideNervous disorderNervous systemMammal
The present invention relates to compounds of the Formulaand pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.
![Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders](https://images-eureka.patsnap.com/patent_img/32f6fa61-a55a-4e38-ab50-2623535a2e62/US08598155-20131203-C00001.png "Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders")
![Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders](https://images-eureka.patsnap.com/patent_img/32f6fa61-a55a-4e38-ab50-2623535a2e62/US08598155-20131203-C00002.png "Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders")
![Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders](https://images-eureka.patsnap.com/patent_img/32f6fa61-a55a-4e38-ab50-2623535a2e62/US08598155-20131203-C00003.png "Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders")
Owner:PFIZER INC
Asenapine Prodrugs
InactiveUS20110166194A1Minimize exposureMinimize diffusionBiocideNervous disorderBipolar type I disorderBipolar I disorder
Compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed:wherein R1-R8, G, N and A− are as defined in the written description.
Owner:ALKERMES INC
Methods of treatment of schizophrenia
ActiveUS8980252B2Low profileImprove complianceNervous disorderPeptide/protein ingredientsSchizophreniaDigestive enzyme
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
Owner:CUREMARK
Methods for treating Parkinson's disease using pro-neurogenic compounds
This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and / or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and / or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
19-nor c3, 3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
ActiveUS20160108080A1Eliminate potential for oxidationImprove bioavailabilityOrganic active ingredientsSenses disorderWithdrawal syndromeSubstance abuse disorder
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful NI for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS
5-Amino-Oxazepine and 5-Amino-Thiazepane Compounds as Beta Secretase Antagonists and Methods of Use
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I); wherein variables A1, A3, A4, A5, A6, A8, R2, R7, X and Y of Formula (I) are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and / or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and sub-formula embodiments of Formula (I) and (II), intermediates and processes and methods useful for the preparation of compounds of Formulas (I)-(II).
Owner:AMGEN INC
Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, L, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and / or caused by the formation and / or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
Owner:AMGEN INC
Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors
The present invention relates to new compounds which are Heterocyclic derivatives of formula (I) wherein A, B, P, X, Y, Q, W, R1 and R2 are defined in the description. Invention compounds are useful for treating central or peripheral nervous system disorders and other disorders which are affected by the neuromodulatory effect of mGluR5 positive allosteric modulators such as cognitive decline and also to treat both positive and negative symptoms in schizophrenia.
Owner:ADDEX PHARM SA
Benzofuranyl alkanamine derivatives and uses thereof
InactiveUS20060247276A1Increase body weightUseful in treatmentBiocideNervous disorderSerotoninMedicine
Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R1, R1′, R2, R3, R4, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
Owner:WYETH LLC
Spiro-Amino-Imidazo-Fused Heterocyclic Compounds as Beta-secretase Modulators and Methods of Use
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I, wherein variables A1, A3, A4, A5, A6, A8, R2, R7, X, Y and Z of Formula I are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and / or conditions related to plaque formation and deposition, resulting from the activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits and impairments, schizophrenia and other central nervous system conditions and disorders. The invention further provides compounds of Formulas II and III, and of sub-formulas of Formulas I, II and III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.
Owner:AMGEN INC
3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
![3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors](https://images-eureka.patsnap.com/patent_img/8b04a2d6-588d-4ccd-b5d6-e968e664d154/US20110306642A1-20111215-C00001.png "3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors")
![3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors](https://images-eureka.patsnap.com/patent_img/8b04a2d6-588d-4ccd-b5d6-e968e664d154/US20110306642A1-20111215-C00002.png "3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors")
![3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors](https://images-eureka.patsnap.com/patent_img/8b04a2d6-588d-4ccd-b5d6-e968e664d154/US20110306642A1-20111215-C00003.png "3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors")
Owner:ADDEX PHARM SA +1
Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
InactiveUS20110166156A1Useful in treatmentSufficient amountBiocideNervous disorderBipolar type I disorderBipolar I disorder
Compounds of Formula I and Formula II and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed.
Owner:ALKERMES INC
1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
Owner:ADDEX PHARM SA +1
19-nor neuroactive steroids and methods of use thereof
ActiveUS20160083418A1Eliminate potential for oxidationInhibit metabolismOrganic active ingredientsSenses disorderSubstance abuserWithdrawal syndrome
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, and status epilepticus.
Owner:SAGE THERAPEUTICS
Compositions for treating CNS disorders
An aminomethylpyridyloxymethyl / benzisoxazole substituted azabicyclic compound, a pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression.
Owner:PFIZER INC
19-nor neuroactive steroids and methods of use thereof
InactiveUS20160068563A1Eliminate potential for oxidationImprove bioavailabilityNervous disorderEstrane derivativesSubstance abuserWithdrawal syndrome
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, status epilepticus.
Owner:SAGE THERAPEUTICS
Beta- and gamma-diketones and gamma-hydroxyketones as wnt/beta-catenin signaling pathway activators
ActiveUS20120046320A1Increase successful activityIncrease cell and tissue regenerationBiocideSenses disorderStem cellWound healing
The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt / β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
Owner:BIOSPLICE THERAPEUTICS INC
Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives
This invention provides compounds of the formula: 1 wherein R.sub.1 and R.sub.2 are each, independently, H, alkyl, cycloalkyl, --CH.sub.2-cycloalkyl, alkoxy, halogen, fluorinated alkyl, --CN, --NH--SO.sub.2-alkyl, --SO.sub.2--NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated alkoxy, acyl, or phenoyl or thiophenoyl; R.sub.3 and R.sub.4 are each, independently, H, alkyl or cycloalkyl; R.sub.5 is H or alkyl; R.sub.6 is H or; and the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions and methods utilizing these compounds for the treatment or prevention of disorders including obsessive-compulsive disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.
![Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives](https://images-eureka.patsnap.com/patent_img/18b7c78f-e97e-45ca-abd5-187dfef2a747/US20020128261A1-20020912-C00001.png "Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives")
![Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives](https://images-eureka.patsnap.com/patent_img/18b7c78f-e97e-45ca-abd5-187dfef2a747/US20020128261A1-20020912-C00002.png "Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives")
![Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives](https://images-eureka.patsnap.com/patent_img/18b7c78f-e97e-45ca-abd5-187dfef2a747/US20020128261A1-20020912-C00003.png "Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives")
Owner:WYETH LLC
Dispersible tablet containing antipsychotic medicines and application thereof
The invention relates to a novel dispersible tablet which is prepared from a certain amount of antipsychotic medicines or pharmaceutically acceptable salt or ester thereof or mixture thereof, a certain amount of selective serotonin reuptake inhibitors (SSRIs) and at least one of pharmaceutically acceptable carriers, wherein the antipsychotic medicines are aripiprazole, fluvoxamine, escitalopram, olanzapine, mirtazapine, clozapine, ziprasidone, mianserin, agomelatine, lurasidone, iloperidone, blonanserin, moclobemide, timiperone, palipeddone, trimipramine, carpipramine, lofepramine or mosapramine. The novel dispersible tablet is used for preventing, delaying or treating depression or schizophrenia of patients. Compared with common tablets or capsules, the novel dispersible tablet has the characteristics of quick and uniform dispersion, short disintegration time, quick medicine absorption, high bioavailability and good stability, and is convenient to take.
Owner:王定豪
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com